ArticleJournal of Cancer2018

Overall survival and post-progression survival are potent endpoint in phase III trials of second/third-line chemotherapy for advanced or recurrent epithelial ovarian cancer.

Mototsugu Shimokawa et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.